2D-radiotherapy in Palliation of Advanced Esophageal Cancer

Short-course Accelerated 2D-radiotherapy in Palliative Treatment of Advanced Esophageal Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03922152

Acronym

SHARON-2D

Enrollment

Registered

2019-04-19

Start date

2009-01-01

Completion date

2019-01-01

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative Care

Keywords

palliative care, radiotherapy, pain, quality of life, esophageal cancer

Brief summary

The study wants to define the efficacy of a short course 2D-radiation therapy in patients with symptomatic advanced esophageal cancer.

Detailed description

The study wants to define the efficacy of a short course accelerated 2D-radiation therapy delivered in twice daily fractions and 2 consecutive days for symptomatic palliation of advanced esophageal cancer.

Interventions

RADIATIONShort course radiotherapy

An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically proven advanced esophageal cancer * excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status * age \> 18 years * Eastern Cooperative Oncology Group (ECOG) \<3

Exclusion criteria

* prior radiotherapy to the same region

Design outcomes

Primary

Measure	Time frame	Description
Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]	1 year	Symptoms were graded using the IAEA scoring system. Values range from 0 (no symptom) to 4 (severe symptom).

Secondary

Measure	Time frame	Description
Incidence of Treatment-Emergent Adverse Events [Acute radiation toxicity]	1 year	Acute toxicity after treatment is evaluated with the Radiation Therapy Oncology Group (RTOG) scale. Values range from 0 (no acute toxicity) to 4 (maximum acute toxicity).
Assessment of the Performance Status	1 year	Performance Status after the treatment is evaluated according with the Eastern Cooperative Oncology Group (ECOG) score. Values range from 0 (better status) to 5 (worst status).
Assessment of the Overall Survival	1 year	Overall Survival is evaluated from the end of radiotherapy to the last date of follow-up. It is calculated in months.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026